TG Therapeutics, Inc.
TG Therapeutics, Inc.
Explore linked clinical trials.16 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Not stated | 2026-09-24 | NCT06143514 | |
| Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 2 | 2026-09-23 | NCT07680946 | |
| A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Recruiting | Not stated | 2026-09-23 | NCT06433752 | |
| An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis (RMS) | Active, not recruiting | Phase 3 | 2026-09-23 | NCT04130997 | |
| A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 2 | 2026-09-22 | NCT07673744 | |
| A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Recruiting | Phase 2 | 2026-09-21 | NCT07503873 | |
| Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis | Relapsing Multiple Sclerosis | Recruiting | Phase 2 / Phase 3 | 2026-09-21 | NCT07220252 | |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) | Relapsing Multiple Sclerosis | Active, not recruiting | Phase 3 | 2026-09-21 | NCT07211633 | |
| A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS) | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Recruiting | Not stated | 2026-09-21 | NCT06433765 | |
| Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | Relapsing Multiple Sclerosis | Recruiting | Phase 3 | 2026-09-21 | NCT05877963 | |
| A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, chronic inflammatory demyelinating polyradiculoneuropathy, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, multiple sclerosis, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, neuromyelitis optica, optic nerve disorder, optic neuritis, paraneoplastic syndrome, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy | Recruiting | Phase 1 | 2026-09-09 | NCT06680037 | |
| Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Recruiting | Not applicable | 2026-07-29 | NCT06864936 | |
| Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel | B-cell Mediated Autoimmune Disorders | Not yet recruiting | Not stated | 2026-05-11 | NCT07577583 | |
| Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Recruiting | Phase 4 | 2026-05-06 | NCT07389590 | |
| Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Recruiting | Phase 4 | 2026-03-17 | NCT07225361 | |
| Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-02-25 | NCT04624633 |